Fast-Her: Fasting Effects on Breast Cancer Treatment
Part of paid clinical trials in Minneapolis, Minnesota.
- Sponsor
- University of Minnesota
- Study ID
- NCT07624617
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Prolonged Fasting — BEHAVIORALDuring prolonged fasting, participants will eat only once daily (dinner), with water, black coffee and tea permitted during fasting hours. Throughout all conditions, participants will continue their prescribed PI3K inhibitor dosing. All medications will be taken at standardized times to ensure consistent pharmacokinetic measurements.
Study Details
We hypothesize that promoting a fasting state will strengthen the anti-cancer effects of PI3K inhibitors in metastatic breast cancer (MBC) treatment. The primary objective of this study is to assess acceptability of prolonged fasting in this population.
Key Dates
- Start date
- Jun 1, 2026
- Status verified
- May 2026
- Primary completion
- Jul 1, 2027
- Completion
- Jul 1, 2027
Study Design
- Enrollment
- 15 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- CROSSOVER
- Primary purpose
- SUPPORTIVE_CARE
Arms
- Active Comparator: Sequence ANormal eating → Washout → Prolonged fasting
- Active Comparator: Sequence BProlonged fasting → Washout → Normal eating
Primary Outcome Measure
Effect of plasma from fasting in patients on PI3K inhibitors on cell viability [ Time Frame: Week 2 of prolonged fasting ]
Central Contacts
- Lisa Chow, MD, MS612-625-8934
Locations (1)
| Facility | City | State | ZIP |
|---|---|---|---|
| University of Minnesota | Minneapolis | Minnesota | 55455 |
Find similar trials in Minneapolis, MN
By condition
By specialty
By research site
Related Studies
- Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast CancerPHASE1 · Recruiting · Olema Pharmaceuticals, Inc. · Gilbert, Arizona
- Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast CancerPHASE1/PHASE2 · Recruiting · Stemline Therapeutics, Inc. · Dothan, Alabama
- Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 MutationPHASE3 · Recruiting · LeonaBio · Scottsdale, Arizona
- PRE-I-SPY Phase I/Ib Oncology Platform ProgramPHASE1 · Recruiting · QuantumLeap Healthcare Collaborative · Birmingham, Alabama